1. Market Research
  2. > Healthcare Market Trends
EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

  • October 2015
  • 62 pages
  • ID: 3411259
In this report:
IN ONE MAJOR UNIVERSITY HOSPITAL IN JAPAN, THE ISOLATION RATE FOR S. AUREUS AMONG UROLOGY INPATIENTS INCREASED IN EACH OF THE FIVE-YEAR PERIODS, FROM ##.##% FOR 1983-1987 TO ##.##% FOR 1998-2002, AND THE RATE OF MRSA SHOWED A SIMILAR INCREASING TREND.
SPECIFICALLY, MRSA INFECTIONS KILL APPROXIMATELY ##,## HOSPITALIZED US PATIENTS ANNUALLY; THIS IS SIMILAR TO THE NUMBER OF DEATHS DUE TO ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), TUBERCULOSIS, AND VIRAL HEPATITIS COMBINED (BOUCHER AND COREY, 2008; CHU ET AL., 2005; KLEVENS ET AL., 2007A).

Summary

Table of Contents

Search Inside

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus - Epidemiology Forecast to 2024

Brief

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections. The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the growing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus, which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, including methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists estimate that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate of ~1.1 percent. The number of hospitalized incident cases of MRSA in the U.S., France (FR), Italy (IT), Spain (ES), UK, and Japan (JP) will increase, with AGRs ranging from ~0.1 percent to ~3.5 percent, but will decrease in Germany (DE), with a negative AGR of ~0.2 percent.

Overview

- The Methicillin-Resistant Staphylococcus aureus EpiCast Report offers an overview of the risk factors and overall trends of MRSA in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). offers an overview of the risk factors, comorbidities, and the overall and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, broken down by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.

- The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The MRSA EpiCast series will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall MRSA market.

- Quantify patient populations in the overall MRSA market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.

- Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
OpGen Inc (OPGN) - Medical Equipment - Deals and Alliances Profile

Alliance Company Profile: OpGen Inc

  • $ 250
  • Company report
  • December 2017
  • by GlobalData

SummaryOpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). ...

Cepheid - Medical Equipment - Deals and Alliances Profile, GlobalData

Cepheid - Medical Equipment - Deals and Alliances Profile, GlobalData

  • $ 250
  • Company report
  • October 2017
  • by GlobalData

SummaryCepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company ...

OpGen Inc (OPGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alliance Company Profile: OpGen Inc

  • $ 250
  • Company report
  • December 2017
  • by GlobalData

SummaryOpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). ...


Download Unlimited Documents from Trusted Public Sources

RedHill Biopharma Ltd. - Investor Report, January 2018

  • January 2018
    41 pages
  • Digestive Syste...  

    Therapy  

    Anti-Infective  

  • United States  

    World  

    Australia  

View report >

Healthcare Industry - Company Report, December 2017

  • December 2017
    83 pages
  • Infectious Dise...  

    R-and-D  

    Vaccine  

  • World  

View report >

RedHill Biopharma Ltd. - Investor Report, December 2017

  • December 2017
    39 pages
  • Digestive Syste...  

    Therapy  

    Anti-Infective  

  • United States  

    World  

    Australia  

View report >

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.